menu
    • menu
    [{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Bell Potter Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Bell Potter Securities","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Bell Potter Securities"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pentosan polysulfate

    Menu

    Pentosan polysulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Australia's Paradigm Biopharmaceuticals Says Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modificati...

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 04, 2023

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 10, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals Receives US FDA Feedback on IND Application for PPS in Knee OA

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 25, 2021

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals has Clear Path Towards Zilosul® OA Phase 3 Clinical Trial and Product Registratio...

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Paradigm Biopharmaceuticals

                            Australia arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Bell Potter Securities

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Paradigm Biopharmaceuticals has Significant Clarity on Development Pathway for Zilusol

                            Details :

                            Product Name : Zilosul

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 20, 2020

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Bell Potter Securities

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth